DDInter1139 DDInter1678
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Mefenamic acid {u} (Compound) downregulates {v} (Gene) ZNF586
ZNF586 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) upregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Mefenamic acid {u} (Compound) downregulates {v} (Gene) ZNF586
ZNF586 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) upregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Eructation
Eructation {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Mefenamic acid (Compound) downregulates ZNF586 (Gene) and ZNF586 (Gene) is upregulated by Sirolimus (Compound)
Mefenamic acid (Compound) upregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Sirolimus (Compound)
Mefenamic acid (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Sirolimus
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Sirolimus
Mefenamic acid (Compound) downregulates ZNF586 (Gene) and ZNF586 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Sirolimus (Compound)
Mefenamic acid (Compound) upregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Sirolimus (Compound)
Mefenamic acid (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Sirolimus (Compound)
Mefenamic acid (Compound) causes Eructation (Side Effect) and Eructation (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)